Foghorn Therapeutics Inc (FHTX) FinancialsFHTXFoghorn Therapeutics Inc

Evaluating the bottom line, Foghorn Therapeutics Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -54.78%, while the net margin is -44.74%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively FHTX converts its operational activities into shareholder value.

In the context of the broader market, FHTX competes directly with industry leaders such as LYEL and ZNTL. With a market capitalization of $371.75M, it holds a leading position in the sector. When comparing efficiency, FHTX's gross margin of 100.00% stands against LYEL's 100.00% and ZNTL's N/A. Such benchmarking helps identify whether Foghorn Therapeutics Inc. is trading at a premium or discount relative to its financial performance.

Foghorn Therapeutics has shown a significant revenue increase, reporting $16.1 million in Q2 2026, which is a 111.8% year-over-year growth. However, the company continues to face net losses, with a net income of -$7.19 million in the same quarter.